National Guideline Clearinghouse | Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.

National Guideline Clearinghouse | Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.

National Institute for Health and Care Excellence (NICE)

• Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.

Guideline Title Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. Bibliographic Source(s) National Institute for Health and Care Excellence (NICE). Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. London (UK): National Institute for Health and Care Excellence (NICE); 2016 Jan 27. 44 p. (Technology appraisal guidance; no. 377).  Guideline Status This is the current release of the guideline. This guideline meets NGC's 2013 (revised) inclusion criteria.